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Abstract 
Introduction: Intravesical administration of 
Bacillus Calmette-Guerin (BCG), following 
transurethral resection of bladder tumour, has been 
shown to reduce recurrence and progression in 
appropriately selected patients with non-muscle 
invasive bladder cancer. The aim of the study was 
to report the local incidence and range of adverse 
events experienced by patients managed with 
intravesical BCG. 
Methods: All patients who received at least 
one dose of intravesical BCG treatment at Mater 
Dei Hospital in 2014 were included in the study. A 
database including demographic, histological and 
chronological data, together with complication type, 
degree and treatment required was created. Patient 
medical files were reviewed and the patients were 
invited to take part in this audit via a telephone 
survey 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results: 55 patients satisfied inclusion criteria 
and were included in the study.  54 patients were 
documented to have had induction BCG, with 
maintenance BCG in 32 patients. 22 of these 
experienced at least 1 adverse event with BCG, 
whilst 33 had no complications. 1 patient had 3 
adverse events, 7 patients had 2 adverse events and 
14 patients had 1 complication. Most adverse events 
were considered to be mild or moderate in severity. 
Storage bladder symptoms accounted for most of 
these adverse events. No death as a consequence of 
intravesical BCG therapy was recorded. 
Conclusion: Intravesical BCG therapy 
remains one of the mainstay therapies in the 
management of bladder cancer. The majority of 
adverse effects recorded were self-limiting or easily 
treatable with oral analgesics or antibiotics. 
 
Keywords 
Bladder cancer, Intravesical Bacillus Calmette 
Guerin, Morbidity. 
 
Introduction 
Transitional cell cancer of the urinary bladder 
remains a common disease in the western world 
despite reduction in smoking habits and legislation 
which has banned carcinogenic industrial 
substances associated with bladder cancer 
causation.  Urothelial bladder cancer is the 7
th
 most 
common cancer diagnosis in males and 17
th
 in 
females world-wide, with a higher incidence in the 
developed world.
1 
At initial presentation, three fourths of bladder 
tumours are non-muscle invasive, this group of 
bladder cancers represent a diverse group of 
tumours with a wide spectrum in their potential for 
recurrence, progression and eventual adverse 
outcomes.
2  
The wide variation in the one-year 
recurrence rate quoted in the literature after initial 
trans-urethral resection, ranging from 15 to 61% 
attests to the heterogeneous character of non-muscle 
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invasive bladder cancer (NMIBC).
3 
The European Organisation for Research and 
Treatment of Cancer (EORTC) has developed 
tables which stratify NMIBC cases into risk 
categories based on number of tumours, tumour 
size, T stage, grade, recurrence history and presence 
of carcinoma in situ.  These tables have been 
externally validated, and are extensively used to 
guide treatment and follow up.
4- 5 
The mainstay of treatment in NMIBC remains 
a good quality endoscopic resection, with second 
re-staging resection in selected cases and various 
regimens of intravesical chemotherapy or 
immunotherapy.
6 
Intravesical immunotherapy is 
also the primary treatment for isolated carcinoma in 
situ of the urinary tract. 
Maintenance immunotherapy with Bacillus 
Calmette Guerin (BCG) is the only intravesical 
therapy which has been shown to reduce both 
recurrence and progression rates in NMIBC, 
however its use is reserved to EORTC intermediate 
and high risk categories in view of its higher 
morbidity compared to intravesical chemotherapy 
regimens.
7- 8 
 
Method 
A retrospective list of patients who received at 
least one dose of intravesical BCG for the treatment 
of non-muscle invasive bladder cancer at Mater Dei 
Hospital in 2014 where included. Index patient list 
was compiled using clinical departmental database 
which is used to register and follow up all patients 
undergoing intravesical BCG therapy. 
All the patients in our cohort received BCG 
OncoTice® strain (MSD Sharp & Dohme GMBH). 
Intravesical BCG instillation follows the Evidence-
based Guidelines for Best Practice in Urological 
Health Care published by the European Association 
of Urology Nurses.
9 
One phial 12.5mg per vial containing 2-8 x 
10
8
 CFU Tice BCG is diluted in 60 mls of sterile 
0.9% saline solution and instilled in the bladder via 
a 10 or 12F bladder catheter using aseptic technique 
and strict infection control measures.   
Induction intravesical BCG protocol involves 
six instillations one week apart, starting not less 
than two weeks after initial diagnostic TURBT, 
with a maintenance protocol consisting of three 
doses of intravesical BCG a week apart at three 
monthly intervals over three years in high risk cases 
of non-muscle invasive bladder cancer. 
A custom designed database was written to include 
demographic, histological and chronological data, 
together with complication type, degree and 
treatment. Data sources included medical case 
notes, departmental intravesical treatment patient 
database and a standard telephone survey one week 
after each BCG dose.  
 
Results 
55 patients where included in the study, all of 
which received at least one dose of intravesical 
BCG in 2014. 46 of these were male and only 9 
being female.  Most of these patients where elderly, 
as show in Figure 1. 
 
Figure 1:  Patient age demographics 
 
 
 
 
 
 
 
 
 
 
 
 
The indications for BCG treatment included 
various subgroups of high risk or recurrent non-
muscle invasive bladder cancer, as showing in 
Table 1.  The indication for BCG treatment was not 
documented in one patient. 54 patients received 
induction BCG, 32 of these went on to received 
maintenance BCG. 
 
Table 1: Tumour characteristics in patients 
undergoing BCG therapy 
 
Indication   
recurrent T1G3 TCC 15 
solitary T1 TCC 9 
multifocal T1 TCC 9 
recurrent T1 TCC 9 
solitary T1 G3 TCC 4 
multifocal G3 TCC 3 
multifocal T1G3 TCC 3 
recurrent CIS 1 
Not available 1 
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22 patients out of 55 experienced at least one 
adverse event with BCG. One patient had three 
adverse events, seven patients had 2 adverse events, 
14 patients had one complication. Most of these 
adverse events were considered to be of mild or 
moderate in severity, with two events qualifying as 
serious adverse event (SAE) by American Food and 
Drug Administration criteria (culture positive UTI 
requiring admission for intravenous antibiotics).  
All other adverse events were either managed 
conservatively or else with simple measures such as 
analgesics, oral antibiotics or delay in the next dose 
of BCG with a good outcome in all cases. No cases 
of mortality from intravesical BCG therapy were 
recorded. The full list of adverse events reported is 
given in Figure 2. Figure 3 outlines the treatment 
administered to manage these complications. 
 
Figure 2: List of adverse events reported in BCG 
treated patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3:  Treatment strategies adopted to manage 
adverse events secondary to intravesical BCG 
therapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
Intravesical Bacillus Calmette-Guérin, an 
attenuated form of the Mycobacterium bovis, has 
been used by urologists for many years following 
first reports of its potential anti-carcinogenic effects 
in 1929 by Pearl.
10 
In an autopsy series he noticed 
that cancer occurred less frequently in individuals 
with active tuberculous lesions compared to healthy 
controls, and postulated that tuberculous infection 
may be protective in this respect.  Morales et al 
were the first to describe intravesical BCG use for 
the treatment of bladder cancer in in 1976, where 
they showed a significantly reduced recurrence rate 
in nine treated patients. The regimen used, 
consisting of six weekly intravesical instillations of 
BCG, is still the most popular induction protocol in 
most centres.
11 
Further investigation in the optimal BCG 
schedule, published by Lamm et al in 2000, which 
showed that progression rates can be reduced by an 
additional maintenance protocol has resulted in the 
widespread adoption of this combined induction-
maintenance schedule for the treatment of high-risk 
non-muscle invasive bladder cancer following 
initial diagnosis at transurethral resection.
12 
Risk stratification in this patient group is 
essential for many reasons.  Non-muscle invasive 
bladder cancer included a heterogeneous cohort of 
patients with very variable cancer specific mortality 
outcomes.  Intravesical BCG therapy has a 
significant morbidity, with a potential for serious 
adverse events, treating low risk patients with 
intravesical BCG has the potential for overtreatment 
and unnecessary morbidity.  In view of this the 
European Organization for the Treatment and 
Research of Cancer (EORTC) has published risk 
stratification nomograms which are used to guide 
patient selection after histopathological diagnosis of 
NMIBC.
13 
In this retrospective study the local morbidity 
from intravesical BCG therapy was assessed and 
compared to similar series. 40% of the patients 
included reported at least one adverse event, which 
is within the published rate of 10-50% in other 
series.
14-16 
Half of the adverse events were reported as 
irritative culture-negative lower urinary tract 
symptoms, this is not surprising and is in keeping 
with the inflammatory bladder reaction which 
invariably follows intravesical BCG instillation.  
Other common reactions included culture positive 
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UTI and haematuria.  Uncommon effects were 
mostly systemic in nature, including malaise and 
fever. This highlights the fact that the adverse effect 
profile of intravesical BCG extends beyond the 
confines of the lower urinary tract, and should be 
considered as a therapeutic modality with potential 
for severe systemic side effects, including 
potentially life threatening BCG sepsis.   
This study has some strengths and numerous 
limitations.  The index case list captures all the 
patients treated with intravesical BCG for the given 
study period at a national level as this therapy is 
administered by one urology unit and a clinical 
database is in place to register and follow up all 
patients receiving BCG treatment.  This also allows 
for standardisation of the BCG strain, dose and 
method of administration across the patient cohort. 
The limitations of this study are mostly related 
to its retrospective nature, which may have resulted 
in incomplete data capture and underestimation of 
adverse events rates.   In addition, patients may 
have presented to their private general practitioner 
or government health centre with minor BCG-
therapy related complaints, and these events may 
have gone unnoticed and unreported by the 
investigators.  In an attempt to limit these 
unreported adverse events all patients where 
contacted by phone a week after their BCG dose 
and the severity of any events were also assessed at 
this time.  Moreover, in the absence of strict 
definitions of drug related adverse events severity, 
the classification of adverse events into mild or 
moderate is somewhat arbitrary.  The FDA   
definition of a serious event was used to identify 
serious morbidity according to established criteria.  
The relatively low number of patients on 
maintenance intravesical BCG may also have had 
an impact on morbidity rates.  This is a matter of 
debate in the urological community as maintenance 
BCG treatment has not been shown to increase 
morbidity in published literature.  However, this 
does highlight the clinical concern that maintenance 
BCG might be underutilised in our unit, especially 
given that most of the patients in this patient cohort 
classify as EORTC high-risk patients.  
 
Conclusions 
Morbidity secondary to intravesical BCG 
therapy in the local population of high-risk non-
muscle invasive bladder cancer patients compares 
favourably to published series.  Adverse events are 
mostly low grade and are managed successfully 
with simple measures in the majority of cases.  
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